The Evolution of Inhaled Therapies: Advancements in Respiratory Disease Management

Seth Hall, Vani Ravichandran, Savan Patel, Gareth Gwyn

The management of respiratory diseases has been revolutionized by inhaled therapies as they offer targeted drug delivery to the lungs. From early nebulizer innovations to newer dry powder inhalers (DPIs), these advancements have transformed care for millions of patients. This article explores the history, benefits, and future potential of inhaled therapies, with a special focus on emerging technologies.

A Brief History of Inhaled Therapies

Inhaled therapies date back nearly 4,000 years. Early medicinal practices such as Ayurveda emerged in India around 2000 BCE, where herbal compounds like *Datura* were inhaled for their bronchodilatory properties (Patwardhan et al., 2005). By 1500 BCE, Egyptians inhaled vapors of black henbane (*Hyoscyamus*), a plant containing hyoscyamine, for respiratory relief (Nunn, 2002). Ancient Greeks, under Hippocrates, developed one of the earliest inhalation devices: a simple pot with a reed for inhaling medicinal vapors (Nutton, 2004). These early practices, also seen in the use of pipes in Central and South America, formed the foundation for modern inhalation therapies (Anderson, 2005; Parameswaran et al., 2018). The evolution of inhaled therapies reflects ongoing innovation in medication delivery. Some common inhalation mechanisms are delineated below.

Nebulizers: The first modern inhalation devices, nebulizers emerged in the 19th century, delivering medication via aerosolized liquid droplets (Anderson, 2005). While effective, traditional nebulizers can be cumbersome due to size and required assembly, along with being time-consuming, and often impractical for daily use.

Metered-Dose Inhalers (MDIs): Introduced in the 1950s, MDIs offered a portable alternative to nebulizers (Dolovich et al., 2005). However, they require precise coordination between actuation and inhalation, presenting challenges for some patients.

Dry Powder Inhalers (DPIs): With the emergence of DPIs in the 1990s, many limitations of earlier devices were addressed. DPIs simplify drug delivery by relying on the patient's inhalation effort to disperse the medication (breath-actuation), enhancing usability and adherence (Lavorini et al., 2008).

Seth Hall, Vani Ravichandran, Savan Patel, and Gareth Gwyn are with Global Medical Affairs at Liquidia Technologies, Inc. in Morrisville, NC.

The Benefits of Direct Lung Delivery

Direct lung delivery has proven to be a cornerstone of effective treatment for respiratory diseases. By administering medication to the lungs, therapeutic agents reach their intended site of action directly, avoiding untoward side effects that result from systemic delivery methods such as oral or IV administration. This localized drug delivery can enable lower therapeutic dosing thereby minimizing toxicity, while providing rapid, targeted relief for symptoms like bronchoconstriction, vasoconstriction, inflammation, and airway obstruction (Parameswaran et al., 2018).

The Advantages and Limitations of Dry Powder Inhalers

Dry powder inhalers (DPIs) have become a preferred choice for many respiratory diseases due to their portability, ease of use, and patient adherence. Unlike MDIs, DPIs do not require precise timing, propellants, or spacers, and their compact design makes them ideal for on-the-go use (Usmani et al., 2021). From a functional perspective, DPIs are breath-actuated and utilize the energy of inhalation to overcome the cohesive forces within the powder, breaking up the particles in a process known as deagglomeration. The resistance within the inhalation device provides mechanical assistance with deagglomeration and distribution of drug particles to the lungs (Newman and Busse, 2020). Despite these technological advancements, inhaled drug delivery efficiency remains poor (Kleinstreuer et al., 2008). For instance, in the case of DPI's, patients with restrictive lung diseases may have limited ability to use higher resistance inhalers, inhibiting complete particle deagglomeration. Inadequate deagglomeration of dry powder increases variability in particle sizes, causing larger particle aggregates to deposit in the oropharynx and upper airways, leading to cough (Grob et al., 2022). Apart from increasing potential upper airway irritation, the resulting insufficient delivery of medication to the lower airways may result in increased systemic absorption, creating additional tolerability challenges for patients. A critical advancement in the inhalation delivery space would be in the development of particles with physical and chemical flow properties that resist aggregation, as this would directly improve the mixture's aerosol distribution (Telko and Hickey, 2005). Such an advancement would enable the use of lower resistance inhalers that require less inspiratory effort for a patient, reducing treatment burden and improving drug delivery efficiency.

A Novel Formulation Approach: PRINT® Technology by Liquidia

PRINT® (Particle Replication in Non-Wetting Templates) technology has the potential to significantly advance the manufacturing of dry powder inhaled DPI formulations (Liquidia, 2025). This next-generation technology offers the unique ability to control inhaled particle sizes and shapes, giving users a higher degree of confidence that the drug reaches the targeted lung region. The geometric precision or shape of these particles can significantly enhance aerosolization, potentially allowing PRINT® engineered formulations to be compatible with a diverse array of DPI devices—ranging from low to high resistance and tailored to the specific pathophysiology of various respiratory conditions. Furthermore, PRINT® technology is designed to ensure homogeneity in particle concentration, a critical factor in maintaining consistent dosing and therapeutic efficacy. This uniformity (Figure 1) potentially mitigates variability in drug delivery, which could result in better patient outcomes (Garcia et al, 2012).



Figure 1. PRINT® particle size and shape uniformity.

Note: Many inhalation powders are made by micronization (jet milling) or spray drying resulting in large particle size distributions. PRINT® technology provides control over particle size and shape for uniformity.

PRINT® particles, which can be as small as 1 micron, also exhibit uniform aerodynamic properties, and are engineered to minimize inter-particle cohesion and provide uniform drug delivery as seen in Figure 2 (Garcia et al, 2012). Consequently, the administration process does not necessitate higher resistance (high patient effort) devices for deagglomeration, enabling the use of user-friendly, low-effort inhalation DPI devices. This novel approach facilitates the production of highly specialized inhaled particles, potentially enhancing therapeutic delivery.



Figure 2. PRINT® torus-shaped particles.

Note: Particle size provides preferential delivery to alveolar region and less upper airway deposition as seen in a canine model using Tc99 scintigraphy with PRINT® particles.

The Future of Inhaled Therapies

The evolution of device technology in concert with advancements in drug formulations holds great promise in improving pulmonary drug delivery. Emerging liposomal formulations may mark a significant milestone in this ongoing effort. Liposomes are nanoscale lipid vesicles that can encapsulate drugs to extend their release profiles, enhance stability, and reduce dosing frequency (Sercombe et al., 2015). These innovations could potentially provide sustained therapeutic benefits for a variety of respiratory illnesses, reducing the burden of frequent dosing, and possibly improving patient adherence.

Conclusion

The development of inhaled therapies demonstrates the relentless pursuit of more tolerable, patient-friendly respiratory treatment options. Innovations such as PRINT® technology and liposomal formulations underscore the commitment to optimizing drug delivery for challenging lung conditions. As research continues, the future of inhaled therapies holds immense potential to address unmet needs and improve quality of life for patients worldwide.

References

1 Anderson, P. J. (2005). History of aerosol therapy: Liquid nebulization to MDIs to DPIs. *Respiratory Care*, *50*(9), 1139-1150.

2 Parameswaran, K., Belda, J., & Brown, N. J. (2018). Pharmacokinetics of inhaled therapies for lung disease. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, *31*(4), 175-190.

3 Patwardhan, B., Warude, D., Pushpangadan, P., & Bhatt, N. (2005). Ayurveda and traditional Chinese medicine: A comparative overview. *Evidence-Based Complementary and Alternative Medicine*, *2*(4), 465-473.

4 Nunn, J. F. (2002). *Ancient Egyptian medicine*. University of Oklahoma Press.

5 Nutton, V. (2004). *Ancient Medicine*. Routledge.

6 Grob, R., Berkenfeld, K., Schulte, C., & Garbacz, G. (2022). Effect of texture and surface chemistry on deagglomeration and powder retention in capsule-based dry powder inhaler. *AAPS PharmSciTech*, *23*, 281.

7 Kleinstreuer, C., Zhang, Z., and Donohue, J. (2008) Targeted drug aerosol delivery in the human respiratory system. *Annual Review of Biomedical Engineering*, *10*, *195-220*.

8 Dolovich, M. B., Ahrens, R. C., Hess, D. R., et al. (2005). Device selection and outcomes of aerosol therapy: Evidence-based guidelines. *Chest*, *127*(1), 335-371.
9 Lavorini, F., Magnan, A., Dubus, J. C., et al. (2008). Aerosol delivery in asthma: Patient considerations for optimizing treatment. *Nature Reviews Drug Discovery*, *7*(10), 807-815.
10 Usmani, O. S., Biddiscombe, M. F., & Barnes, P. J. (2021). Regional lung deposition and persistence of the corticosteroid ciclesonide in asthma. *Respiratory Medicine*, *107*(11), 1871-1882.
11 Newman, S. P., & Busse, W. W. (2020). Evolution of dry powder inhaler design and integration into clinical practice. *Therapeutic Advances in Respiratory Disease*, *14*, 1-12.
12 Chow, A. H. L., Tong, H. H. Y., Chattopadhyay, P., et al. (2022). Particle engineering for pulmonary drug delivery. *Pharmaceutical Research*, *29*(9), 2111-2130.
13 Liquidia Technologies. (2025). PRINT technology: A revolutionary approach to particle engineering. Retrieved from liquidia.com.
14 Telko, M and Hickey, A. (2005). Dry power inhaler formulation. *Respiratory Care*, *50(9)*, 1209-1227.
15 Sercombe, L., Veerati, T., Moheimani, F., et al. (2015). Advances and challenges of liposomal drug delivery. *Frontiers in Pharmacology*, *6*, 286.
16 Garcia, A., Mack, P.,Williams, S., et al. (2012). Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications. *Journal of Drug Delivery*, *1*, 2090-3014.